Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avapritinib extension study for GIST patients
NCT04825574Phase 4Completed
- Sponsor
- Blueprint Medicines
- Start
- May 2021
- Primary completion
- Nov 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of avapritinib in gastrointestinal stromal tumor (GIST), sponsored by Blueprint Medicines. Started May 2021; status: completed.
02
Drugs
avapritinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT04825574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04825574.